What are COVID-19 antibodies, is there a certain level needed for protection, and how well do COVID-19 vaccines work in people with cancer? In this Q&A, NCI experts discuss emerging research findings from the SeroNet program that are shedding light on these and other important questions.
National Cancer Institute (NCI) on LinkedIn: Bacteria inside lung tumors concentrate within cancer cells
The Importance of Building Trust in COVID-19 Vaccines
NCI to distribute IL-6 inhibitor for cancer patients with COVID-19 lung inflammation - The Cancer Letter
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
News from NCI about COVID-19 - NCI
Ohio State Researchers Cross Disciplines to Establish National STOP-COVID Center
National Cancer Institute (NCI) on LinkedIn: Study Identifies Crucial Characteristic of High-Risk HPV
neutralizing antibodies – NIH Director's Blog
Antibody characterisation – an essential researchers' resource
Vaccine Therapies for Cancer: Then and Now
With $306M for serology research, NCI mobilizes labs, academic centers, grantees, contractors, and SBIR - The Cancer Letter
Antibody (Serology) Tests for COVID-19: a Case Study - ScienceDirect
neutralizing antibodies – NIH Director's Blog
Vaccines, Free Full-Text
Antibodies and Vaccines as Drugs for COVID-19, keystone symposia
